news FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID. By Brian Park, PharmD Publish Date December 1, 2020
